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Mortality and morbidity among patients with 
heart failure (HF) remain high, despite advances 
in therapy. 
Heart failure with preserved ejection fraction 
(HFpEF) is driven by diminished left ventricle 
relaxation and elevated filling pressures, all of 
which lead to pulmonary congestion [1, 2]. In these 
patients, therapeutic options impacting prognosis 
are limited.
Recently, a novel therapy has been proposed. 
It is based on creating a communication between 
both atria using a trans-septal puncture and balloon 
septostomy. The concept is based on the well-
known Lutembacher syndrome, which is defined 
as a combination of mitral stenosis and atrial septal 
defect (ASD). The left to right interatrial shunt 
enables decompression of the left atrium and thus, 
may improve patient symptoms.
Moreover, observations made in elderly sub-
jects with masked left ventricle restriction, who un-
derwent ASD closure, showed that temporary ASD 
occlusion with a balloon resulted in significant ele-
vated left atrial pressure [3]. A fenestrated ASD sep-
tal occlude has been designed to enable bidirection-
al flow both in systolic and diastolic impairment [4]. 
Implantable pressure systems have provided data 
that left atrial pressure is highly variable over the 
course of a day and sustained elevations precede 
clinical events, averaging > 25 mmHg for several 
days before admission or death [5]. 
Therefore, a therapy focused on decreasing 
left atrial filling pressures seems to be promising.
Several small studies proved initial safety 
and efficacy of three different interatrial shunting 
devices in therapy for patients either with heart 
failure with reduced ejection fraction (HFrEF) or 
HFpEF [6, 7]. There are three different devices 
available for patients with either HFrEF or HFpEF: 
interatrial shunt device (IASD, Corvia Medical Inc., 
Tewksbury, MA, USA), V-Wave shunt (V-Wave Ltd., 
Caesarea, Israel) and Atrial Flow Regulator (AFR, 
Occlutech, Heslingborg, Sweden). 
Atrial Flow Regulator is a self-expandable 
a double-disc nitinol wire mesh construction allow-
ing communication across the interatrial septum 
(Fig. 1). In contrast to V-wave and IASD, it is 
available in different sizes. The offered fenestra-
tion diameter ranges from 4 to 10 mm, but for 
HF patients only 8 mm and 10 mm have the Eu-
ropean Conformité Européenne (CE) mark. Ad-
ditionally, there are two available heights of the 
device: 5 and 10 mm, chosen according to intera-
trial septal thickness. The device is repositionable 
and retrievable.
First AFR implantation in Poland was done in 
a 28-year-old patient with severe pulmonary arte-
rial hypertension (PAH) [8]. More recently, AFR 
has been successfully used as a bridge to lung 
transplantation in a young patient with drug-
resistant idiopathic PAH [9].
Recently four AFR devices in patients with 
severe HFrEF were successfully implanted. 
These procedures were done as a part of ongoing 
PROLONGER trial (Pomeranian atRial flOw 
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Herein presented, are the results of a 66-year- 
-old male with HFrEF (LVEF 25%), history of 
three myocardial infarctions, arterial hyperten-
sion and paroxysmal atrial fibrillation. Despite an 
optimal therapy, the patient remained symptomatic 
with New York Heart Association (NYHA) III. His 
6-minute walk test distance (6MWT) was 200 m. 
The patient underwent diagnostic right heart cath-
eterization with the Swan-Ganz catheter, which 
revealed decreased cardiac output accompanied 
with significantly increased pulmonary artery 
wedge pressure (PAWP).
According to PROLONGER protocol, hemo-
dynamic indications for AFR are: PAWP above 
15 mmHg or 25 mmHg at rest and exertion re-
spectively. A right atrial pressure above 20 mmHg 
or exceeding PAWP is the contraindication for an 
atrial shunting procedure.
The AFR procedure was performed under gen-
eral anesthesia. A three-dimensional transesopha-
geal echocardiography (TEE) guided trans-septal 
puncture was performed followed by a 12 mm 
balloon septostomy. An AFR (8 mm fenestration, 
5 mm height) was successfully implanted using 
a 12 F dedicated delivery system. The left to right 
mean gradient obtained from TEE was 2.7 mmHg. 
The patient was discharged home on the third day. 
As the patient had a history of atrial fibrillation, he 
was given non-vitamin K antagonist oral antico-
agulants. There was no other specific indication 
for anticoagulation in this patient, because flow 
through the device was left to right. 
The first follow-up visit after 1 month was 
complete, significant clinical improvement was 
noticed. The patient moved from NYHA III to 
NYHA II and 6MWT distance increased from 200 m 
to 397 m. Diagnostic right heart catheterization 
revealed significant reduction in PAWP, mean pul-
monary artery and right atrial pressures (Fig. 2). 
The mean left to right gradient in TEE was 
10 mmHg compared to 2.7 mmHg directly after 
AFR implantation. This difference could be ex-
plained by the fact that left atrial pressure had 
changed dynamically according to fluid overload, 
exertion and other conditions. Similar variability 
in all 4 patients thus far were observed.
The second follow-up visit was scheduled  at 
2 months.
This  experience with AFR device is a promis-
ing option for patients with severe HF and further 
results will be published soon.
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Figure 2. Hemodynamic parameters taken from diagnos-
tic right heart catheterization before, and 1 month after 
implantation of Atrial Flow Regulator (AFR); CVP — cen-
tral venous pressure; PAWP — pulmonary artery wedge 
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Figure 1. Atrial Flow Regulator (AFR, Occlutech, Hes-
lingborg, Sweden).
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